Treatment of Penile Fungal Infection (Candidal Balanitis)

First-Line Treatment Approach

The Centers for Disease Control and Prevention (CDC) recommends treating penile fungal infections (candidal balanitis) with topical antifungal agents applied to the affected area for symptom relief 1, 2
The CDC guidelines recommend topical antifungal agents to relieve symptoms in male partners with balanitis, characterized by erythematous areas on the glans of the penis with pruritus or irritation 1, 2, 3
Clotrimazole 1% cream is recommended to be applied to the affected area twice daily for 7-14 days 1
Miconazole 2% cream is recommended to be applied to the affected area twice daily for 7-14 days 1

Most uncomplicated cases respond within 7-14 days of topical therapy 1
Topical agents usually cause no systemic side effects, though local burning or irritation may occur in some patients 1, 4

For patients with severe symptoms or recurrent infections, consider oral fluconazole 150 mg as a single dose 1, 5
Treatment of female sexual partners is not routinely recommended unless the woman has recurrent vulvovaginal candidiasis 1, 2, 3
Candidal balanitis is not typically sexually transmitted, though it can occur in male partners of women with vulvovaginal candidiasis 1, 6

Do not use oral azoles as first-line therapy for uncomplicated penile candidal infections—topical therapy is equally effective with fewer systemic risks and drug interactions 1, 4
Be aware of drug interactions if oral azoles are prescribed: they interact with calcium channel antagonists, warfarin, cyclosporine, oral hypoglycemics, phenytoin, protease inhibitors, and many other medications 1, 4
Consider non-albicans species (particularly Candida glabrata) in refractory cases, as these may require longer treatment duration or alternative agents 1, 3

Patients should return for follow-up only if symptoms persist or recur after completing the initial treatment course 1, 2
Routine follow-up is not necessary for uncomplicated cases that respond to therapy 1
For recurrent infections, consider evaluating for predisposing factors such as diabetes mellitus, immunosuppression, or poor hygiene practices 6

In documented fluconazole-resistant C. albicans infections, oral itraconazole has demonstrated efficacy when in vitro susceptibility testing shows sensitivity to this agent, and testing for antifungal susceptibility should be considered when treatment failure occurs or with prior azole exposure, as recommended by the Infectious Diseases Society of America 7

In patients with severe candidal balanitis, a single oral dose of fluconazole 150 mg is the appropriate regimen; a daily dose of 100 mg for three days is reserved for moderate‑to‑severe oropharyngeal candidiasis and should not be used for balanitis. [8][9]

Topical antifungal agents (e.g., clotrimazole 1 % cream) produce no systemic adverse effects, although local burning is reported in approximately 5–10 % of patients. [CDC (MMWR 2002) 10]

Before prescribing oral azole antifungals, clinicians should review the patient’s medication list because fluconazole can interact with calcium‑channel blockers, warfarin, cyclosporine, oral hypoglycemics, phenytoin, and protease inhibitors. [CDC (MMWR 1993) 11]
Hepatotoxicity from oral azoles is rare (approximately 1 case per 10,000–15,000 exposures with ketoconazole) and the most common side effects are nausea, abdominal pain, and headache. [CDC (MMWR 1993) 11]

Patients should be instructed to return for evaluation only if symptoms persist after treatment or recur later; routine follow‑up is unnecessary for uncomplicated cases that respond to therapy. [CDC (MMWR 2002) 10]
In cases of recurrent balanitis (≥ 3 episodes per year), clinicians should assess for underlying conditions such as diabetes mellitus, immunosuppression, or HIV infection. [CDC (MMWR 1993) 11]

Routine antifungal treatment of female sexual partners is not recommended unless the partner has documented recurrent vulvovaginal candidiasis. [CDC (MMWR 2002) 10]
Candidal balanitis is generally not considered a sexually transmitted infection, although it may occur in male partners of women with vulvovaginal candidiasis. [CDC (MMWR 2002) 10]